Mogelijk gemaakt door 
Translate
Translate
ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
20 January 2026 at 08.30 EET
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 16 January 2026 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
| % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % (points A + B) | Total number of shares and voting rights of issuer |
Resulting situation on the date on which threshold was crossed or reached | 5.00% shares | 0.00% shares | 5.00% shares | 141,134,278 shares |
Position of previous notification (if applicable) | Below 5% shares | Below 5% shares | Below 5% shares |
|
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
Class/type of shares | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) |
FI0009014377 |
| 7,060,661 shares |
| 5.00% shares |
POINT A SUBTOTAL | 7,060,661 shares | 5.00% shares | ||
Point B: Financial instruments according to SMA 9:6a:
Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
American Depositary Receipt (US68628Y1047) | N/A | N/A | Physical | 192 shares | 0.00% shares |
|
|
| POINT B SUBTOTAL | 192 shares | 0.00% shares |
Orion Corporation
Liisa Hurme |
| Mikko Kemppainen |
|
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.
